Abstract: The present invention relates to the field of generating gaseous hydrogen at high pressures and with high purity via electrolysis of water by means of an electrolyzer unit (100) with a novel structure.

Abstract: An electrolyzer cell, electrolyzer setup, and related methods are provided for converting gaseous carbon dioxide to gas-phase products at elevated pressures with high conversion rates via electrolysis performed by the electrolyzer cell (100?). The electrolyzer cell (100?) is a multi-stack CO2 electrolyzer cell having individual stacks (40) that each include bipolar plate assemblies that have unique gas and fluid flow architecture formed therein.

Abstract: The present invention relates to the field of generating gaseous hydrogen at high pressures and with high purity via electrolysis of water by means of an electrolyzer unit (100) with a novel structure.

Abstract: A mesofluidic reactor performs a chemical reaction of a starting material. A liquid phase starting material is introduced into a spraying head equipped with an ultrasound generating piezoelectric crystal unit. An inert/reagent gas feeds into the spraying head, connected to a reactor tube arranged within a thermally insulated multi-zone heating unit. For solid phase, an inert/reagent gas is introduced into a solids container connected to a spraying head equipped with an ultrasound generating piezoelectric crystal unit. The spraying head connects to a reactor tube arranged within a thermally insulated multi-zone heating unit. In either case, a reactor tube outlet connects to a cooled product trap to collect conversed substances. The spraying head generates a particle size distribution with nano and micro sized particles for the liquid phase and nano, micro or larger particles for the solid phase. The inert/reagent gas is preheated over the piezoelectric crystal unit's surface.

Abstract: A mesofluidic reactor performs a chemical reaction of a starting material. A liquid phase starting material is introduced into a spraying head equipped with an ultrasound generating piezoelectric crystal unit. An inert/reagent gas feeds into the spraying head, connected to a reactor tube arranged within a thermally insulated multi-zone heating unit. For solid phase, an inert/reagent gas is introduced into a solids container connected to a spraying head equipped with an ultrasound generating piezoelectric crystal unit. The spraying head connects to a reactor tube arranged within a thermally insulated multi-zone heating unit. In either case, a reactor tube outlet connects to a cooled product trap to collect conversed substances. The spraying head generates a particle size distribution with nano and micro sized particles for the liquid phase and nano, micro or larger particles for the solid phase. The inert/reagent gas is preheated over the piezoelectric crystal unit's surface.

Abstract: The invention relates to a nanostructured (nanoparticular) composition comprising Indomethacine, its pharmaceutically acceptable salts and co-crystals, processes for the preparation thereof, and compositions useful for pharmaceutical applications. The size of the nanoparticles according to the invention is smaller than 500 nm. Indomethacine (INN) or Indomethacine (USAN, previously BAN) is a non-steroidal anti-inflammatory drug (NSAID), which is used for the treatment of fever, inflammation, spasm, swells and inflammations. The machanism of action of Indomethacine is the inhibition of the synthesis of prostaglandin. It is marketed under the trade names of Indocin, Indocid, Indochron E-R, and Indocin-SR.

Abstract: The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.

Abstract: A continuous flow system for the synthesis of nanoparticles includes a feeding unit connected to the first reactor a flow path, at least one first reactor unit possessing a heatable reactor-zone, a second reactor unit which follows the first reactor in the same cascade; a mixing unit and a second feeding unit between the reactor units, and feeding pumps connected to a raw material source and/or a control unit which is capable of controlling at least one pressure controller and/or controlling the temperature of at least one heatable reactor-zone; each heatable reactor-zone is followed by a cooling unit in the cascade. In addition, a process for the synthesis of nanoparticles, preferably metal-containing nanoparticles, and nanoparticles of biologically active organic molecules wherein the process is accomplished using the system.

Abstract: The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine.

Abstract: The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.

Abstract: The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions containing them according to the invention have an average particle size of less than about 500 nm. Sildenafil citrate is inhibiting cGMP specific phosphodiesterase type 5 (PDEV), an enzyme that regulates blood flow in the penis. The compositions of the invention are useful in the treatment of male or female sexual dysfunction and pulmonary arterial hypertension (PAH).

Abstract: The invention relates to a porous electrode used in an electrochemical cell, containing a carrier and/or catalytic agent, which is characterized by that it consists of two or more layers with different average pore sizes, out of which layers the contact layer with the smallest average pore size is in contact with the membrane, and one or more supporting layers with a greater average pore size are linked to the other side of this contact layer. Furthermore, the invention relates to a procedure for the manufacturing of such electrodes and to electrochemical cells containing such electrodes.

Abstract: A process for hydrogenating a sample in a pressure range below supercritical pressure values includes supplying at least a solvent of the sample to be hydrogenated by a feed pump with a constant volume rate into a flow path to create a base solution; adding the sample being dissolved into the flow path; feeding hydrogen into the flow path through a valve configured to transmit hydrogen only into a single direction; leading the dissolved sample in the presence of a catalyst through a hydrogenation reactor, where the reactor is inserted into a section of the flow path located after the hydrogen feeding position; maintaining the pressure of the reaction in a given pressure range by element of a pressure-adjusting unit, and collecting a hydrogenate formed within the hydrogenation reactor in a product receptacle connected to the end of the flow path.

Abstract: The subject of the invention is the (50) continuous flow system for the synthesis of nanoparticles which consist of the (1a) feeding unit connected to the flow path, at least one (2) first reactor unit possessing the (13) heatable reactor-zone, the (3) second reactor unit which follows (2) in the same cascade; the (5) mixing unit and the (1b) second feeding unit between (2) and (3) reactor units, the (9) and (10) feeding pumps connected to the raw material source and/or (22) control unit which is capable of controlling at least one (18) pressure controller and/or controlling the temperature of at least one (13) heatable reactor-zone; each (13) heatable reactor-zone is followed by (14) cooling unit in the cascade. In addition, the subject of this invention is a process for the synthesis of nanoparticles, preferably metal-containing nanoparticles, and nanoparticles of biologically active organic molecules wherein the process is accomplished in the device according to FIG. 1.

Abstract: The present invention relates to a method of forming a sealed channel on the surface of a sheet made of a material with a particular extent of plasticity, the sheet forming a reactor block for a microfluidic reactor.

Abstract: A process for hydrogenating a sample in a pressure range below supercritical pressure values includes supplying at least a solvent of the sample to be hydrogenated by a feed pump with a constant volume rate into a flow path to create a base solution; adding the sample being dissolved into the flow path; feeding hydrogen into the flow path through a valve configured to transmit hydrogen only into a single direction; leading the dissolved sample in the presence of a catalyst through a hydrogenation reactor, where the reactor is inserted into a section of the flow path located after the hydrogen feeding position; maintaining the pressure of the reaction in a given pressure range by element of a pressure-adjusting unit, and collecting a hydrogenate formed within the hydrogenation reactor in a product receptacle connected to the end of the flow path.